Connect Biopharma Holdings Limited
CNTB
$0.7901
-$0.0099-1.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.27% | 48.27% | -8.24% | -8.24% | -23.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 87.87% | 87.87% | -87.87% | -87.87% | 259.78% |
| Total Operating Expenses | -15.06% | -15.06% | -45.54% | -45.54% | -37.12% |
| Operating Income | 20.44% | 20.44% | 117.81% | 117.81% | 37.12% |
| Income Before Tax | 26.80% | 26.80% | 125.35% | 125.35% | 47.13% |
| Income Tax Expenses | 191.07% | 191.07% | -6.25% | -6.25% | -70.71% |
| Earnings from Continuing Operations | 26.41% | 26.41% | 125.10% | 125.10% | 47.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.41% | 26.41% | 125.10% | 125.10% | 47.20% |
| EBIT | 20.44% | 20.44% | 117.81% | 117.81% | 37.12% |
| EBITDA | 20.55% | 20.55% | 119.04% | 119.04% | 37.31% |
| EPS Basic | 26.68% | 26.68% | 125.07% | 125.07% | 47.26% |
| Normalized Basic EPS | 24.34% | 24.34% | 128.10% | 128.10% | 42.54% |
| EPS Diluted | 26.72% | 26.72% | 125.07% | 125.07% | 46.93% |
| Normalized Diluted EPS | 24.34% | 24.34% | 127.93% | 127.93% | 42.54% |
| Average Basic Shares Outstanding | 0.36% | 0.36% | 0.17% | 0.17% | 0.11% |
| Average Diluted Shares Outstanding | 0.36% | 0.36% | 0.91% | 0.91% | 0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |